Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN3 | Q9UGI6 | 7/20 | 0.48 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.46 |
| ▸ | KCNN2 | Q9H2S1 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22413208 | 0.89 | KCNN3 (0.58) | KCNN3KCNN1KCNN2GSK3BPDE2A | |
| SCHEMBL30872083 | 0.82 | KCNN3 (0.49) | KCNN3KCNN1KCNN2GSK3BCDK2 | |
| SCHEMBL22413318 | 0.82 | MAPKAPK2 (0.42) | GSK3BCDK2 | |
| SCHEMBL12954018 | 0.82 | CDK2 (0.52) | KCNN3KCNN1KCNN2GSK3BCCNT1 | |
| SCHEMBL30083507 | 0.81 | GPR39 (0.41) | KCNN3KCNN1KCNN2GSK3BCDK2 | |
| SCHEMBL30083511 | 0.80 | KCNN3 (0.42) | KCNN3KCNN1KCNN2GSK3BCDK2 | |
| SCHEMBL22413282 | 0.80 | CDK2 (0.53) | KCNN3KCNN1KCNN2GSK3BCDK2 | |
| SCHEMBL22413175 | 0.80 | NTRK1 (0.40) | CCNT1NTRK1 | |
| SCHEMBL30083523 | 0.80 | KCNN3 (0.44) | KCNN3KCNN1KCNN2GSK3BCDK2 | |
| SCHEMBL22413162 | 0.80 | CCNT1 (0.54) | GSK3BCCNT1CDK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144841-A1 | TRISUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AS CDK7 INHIBITORS | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE | 2022-05-12 | — | — | US | disclosed |
| WO-2020186196-A1 | TRISUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AS CDK7 INHIBITORS | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020186196-A1 | TRISUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AS CDK7 INHIBITORS | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144841-A1 | TRISUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AS CDK7 INHIBITORS | CDK7, CDK8, CDK3 | KCNN3 4365/4885KCNN1 4614/4885KCNN2 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.